|May 8, 2014|
|07:26 EDT||LCI||Lannett shares should be bought on weakness, says Oppenheimer|
After Lannett reduced its Q4 guidance but provided higher than expected FY15 revenue guidance based on price increases it has implemented, Oppenheimer believes that investors should be pleased with the overall guidance. The firm keeps a $49 price target and Outperform rating on the stock.
News For LCI From The Last 14 Days
|September 2, 2015|
|16:36 EDT||LCI||Lannett up 9.1% after announcing that it will acquire Kremers Urban |
|16:35 EDT||LCI||Lannett to acquire Kremers Urban Pharmaceuticals For $1.23B|
Subscribe for More Information
|16:34 EDT||LCI||Lannett to acquire Kremers Urban Pharmaceuticals For $1.23B|
|August 26, 2015|
|08:44 EDT||LCI||Lannett steady execution offers compelling upside, says Susquehanna|
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
|August 25, 2015|
|16:08 EDT||LCI||Lannett sees FY16 CapEx $60M-$70M|
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
|16:06 EDT||LCI||Lannett sees FY16 revenue $425M-$435M, consensus $433.55M|
|16:05 EDT||LCI||Lannett reports Q4 EPS 91c, consensus 86c|
Reports Q4 revenue $99.3M, consensus $97.62M.